Iovance Q2 net loss narrows

Iovance Biotherapeutics

06/08/2026 12:34

Overview
U.S. TIL therapy maker's Q2 revenue rose 66% yr/yr to record high, driven by Amtagvi demand
Q2 net loss, operating loss and pretax loss all beat analyst expectations
Gross margin improved to 56% on higher Amtagvi sales and manufacturing efficiencies

Outlook
Company is reviewing FY26 revenue guidance of $350 mln to $370 mln; update expected in 3Q26
Iovance expects improvements in gross margin to continue, excluding occasional one-time items
Company expects at least 110 authorized treatment centers active by end of 2026

Result Drivers
AMTAGVI DEMAND - Record Amtagvi demand, supported by a new marketing campaign and expanded sales team, drove increased adoption and revenue
MANUFACTURING EFFICIENCIES - Continued cost optimization and maturing internal manufacturing efficiencies contributed to higher gross margin
TREATMENT CENTER EXPANSION - Growth of the authorized treatment center network and increased physician awareness supported broader adoption

Company press release: ID:nGNX6J02hs

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Revenue
 
$99.31 mln
 
Q2 Net Loss
Beat
$47.32 mln
$57.64 mln (7 Analysts)
Q2 Operating Income
Beat
-$51.91 mln
-$59.66 mln (6 Analysts)
Q2 Pretax Loss
Beat
$48.69 mln
$59.77 mln (7 Analysts)

Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Iovance Biotherapeutics Inc is $9.00, about 107.4% above its August 5 closing price of $4.34

Reuters Recommended Reads
Aug 5 - Adicet Bio Q2 net loss narrows
Aug 5 - Mirum Pharmaceuticals Q2 sales rise, lifts outlook
Aug 3 - TG Therapeutics Q2 product revenue rises 70% on BRIUMVI sales

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)